

Supplementary Fig. 1 In-gel hybridization with ³²P-labeled *mcr-1* gene probe after PFGE of nuclease S1 digested genomic DNA. Lanes from left to right are as followed: PN16 (D0 vs D14), PN21 (D0 vs D14), PN23 (D0 vs D14), PN24 (D0 vs D14), PN25 (D0 vs D14), PN42 (D0 vs D14) and PN43 (D0 vs D14).



Supplementary Fig. 2 Genetic contexts of *mcr-1* on plasmids and *E. coli* chromosome. A. the flanking regions (approx.10kb) of *mcr-1*-carrying contigs from seven *E. coli* isolates from Thailand. The seven HLCRMs showed no amino acid mutations in *mcr-1*-carring contigs including their promoter and the immediate surrounding genetic contexts. The arrow indicated the ORFs and orientation of transcription, and the length of arrow represented the size of corresponding CDS. **B and C**, showed the complete genetic structure of plasmids from isolates PN16, PN21, PN23, PN24, PN25, and PN42. '*hp*' indicates hypothesis protein.

E. coli TOP10::pBAD induced



Supplementary Fig. 3 TEM micrographs of control cells: *E. coli* TOP10 with pBAD minus mcr-1 with L-arabinose induction (0.2%), cells are intact with a well-define inner and outer-membrane, and showed a highly homogeneous electron density in cytoplasm region. This result can rule out effects caused by high concentration of L-arabinose.



Supplementary Fig. 4 *In vitro* growth curve of *mcr-1* derivatives and a negative control. The means of three independent replicates were shown and the error bars represent the S.D (n=3).



Supplementary Fig. 5 TEM micrographs of *mcr-1* **mutants.** A and B, TEM micrographs of *mcr-1* mutation implicated in its active site, E246A, and MCR-1 soluble domain, respectively. C, TEM micrographs of a negative control, *bla*_{TEM-1b}, a highly homogeneous electron density in cytoplasm region were observed.



Supplementary Fig. 6 ESI-QTOF/MS revealed the PEA modification of bacterial lipid A mediated by *MCR-1* gene. A, ESI-MS/MS spectrum of the negative ion of the lipid A extracted from the constructed control strains *E. coli* W3110+ pUC19. The lipid A has a prominent peak at m/z 1797.10 and no PEA modification existed at m/z 1920. B, ESI-MS/MS spectrum visualization of the negative ion of the lipid A extracted from the constructed positive strains *E. coli* W3110 + pUC19-*mcr-1*. A PEA (123u) is added into the bis-phosphorylated hexaacylated lipid A (m/z 1920).

Note: In this study, the bacterial lipid A was analyzed using Waters Synapt HR mass spectrometry under two different ion channels (m/z 1797 and m/z 1920).

TOF MSMS 1920.10ES-: Selected ion monitoring of the product of lipid A modification at m/z 1920.10 with negative ion scan

TOF MSMS 1797.20ES-: Selected ion monitoring of the bacterial lipid A at m/z 1797.20 with negative ion scan



Supplementary Fig. 7 Acquisition and stability of high-level colistin resistance mutants. Changes in colistin minimum inhibitory concentrations (MICs) during 14-day challenging with increasing concentrations of colistin, in seven wild type MCRPEC (A) and three laboratory strains (B). C, the recovery of colistin resistance phenotype in high-level colistin mutants after 14-day passage in colistin-free medium. The resistance ratios represent the ratio between colony-forming units (CFUs) of colistin resistance cells and the total CFUs including resistant strains and susceptible strains.



Supplementary Fig. 8 Expression changes of *mcr-1* gene in HLCRMs mutants, comparing to their parental strains. Fold changes of *mcr-1* expression were obtained by the $\Delta\Delta$ CT analysis method using mean CT value (n=2).





Supplementary Fig. 9 *In vitro* **growth curve of seven** *mcr-1* **positive strains and their derivatives. A-G**, indicated the growth curves of seven WT strains (PN16, 21, 23, 24, 25, 42 and 43) and their derivatives (samples from serial time points: D0, D3, D7, D11 and D14). **H**, indicated the growth rate of *E.coli* TOP10 (*mcr-1*::pBAD) and their derivatives (samples from serial time points: D0, D3, D4, D8 and D14). The OD₄₉₂ value was determined at every one hour. The means of three independent replicates were shown and the error bars represent the S.D (n=3). * for strain PN16, its day-14 mutant are unable to grow, so we tested day-13 mutant instead.



Supplementary Fig. 10 individual *Galleria Mellonella* **killing models.** A-G, indicated *G. Mellonella* killing curves in seven WT strains (PN16, 21, 23, 24, 25, 42 and 43) and their respective mutants with series time points D0, D3, D7, D11 and D14.



Supplementary Fig. 11 *In vitro* growth curve of six *mcr-1* positive E.coli (MCRPEC) and their counterpart non-MCRPEC. The means of three independent replicates were shown and the error bars represent the S.D (n=3).

Supplementary Table 1 Characteristics of MCR-1 carrying bacteria(MCRPEC) and non-MCRPEC											
No.	Date of isolati on	Source	Colistin MICs(m g/l)	MLST*	<i>mcr-1</i> location	Plasmid (type/size)	<i>mcr-1</i> copy number	Additional resistance gene	reference		
PN16	27/10/ 2013	chicken meat	8	ST-2040	plasmid	IncI2 /60,488 bp	3.1	aadA1,blaTEM-1b, blaCMY-2, QnrS1, cmlA1, Sul3, Tet(M)	This study		
PN21	12/02/ 2014	chicken faeces	4	ST-24**	plasmid	IncI2 /60,989bp	2.1	acc(3)-Iid, blaTEm-1A, blaCTX-M-55, QnrS1, fosA, tetA	This study		
PN23	22/02/ 2014	duck faeces	8	ST-1121	plasmid	IncX4 /33,858bp	5.6	tet(B)	This study		
PN24	22/02/ 2014	duck faeces	4	ST-3631	plasmid	IncX4 /35,075bp	4.3	aadA1, adc(3)-Iid, aadA2, blaTEM-1B, blaCTX-M-55, QnrS1, mef(B), catA2, cmlA1, sulA2, tet(A), dfrA12	This study		
PN25	22/02/ 2014	duck faeces	8	ST-101	plasmid	IncX4 /34,117bp	1.8	blaCTX-M-14, tet(B)	This study		
PN42	15/11/ 2013	faeces from healthy human	4	ST-744	plasmid	IncX4 /32,995bp	3.2	aph(3')-la, strA, strB, aadA1, acc(3)-Iid, aadA5, aadA2, blaCTX-M-55, blaCTX-M-14, blaTEM-1B, QnrS1, Mph(A), mef(B),catA1, cmlA1, sul2, sul3, sul1, tet(B), dffA17, dfrA12	This study		
PN43	15/11/ 2013	faeces from healthy human	4	ST-410	chromosom e	NA	1	aadA2,aadA1, aac(3)-11d, blaTEM-IIB, blaCTX-M-55, QnrSI, inu(F), cmlA1, catA2, floR, sul2, sul3, tetA, tetM, dfrA12	This study		
ff112 [#]	-	Human	0.5	ST-638	-	-	-	-	This study		
ff141 [#]	-	Human	0.5	ST-589	-	-	-	-	This study		
ff156 [#]	-	Human	0.5	ST-127	-	-	-	-	This study		
CX37	-	Human	0.5	ST-648	-	-	-	-	1		

* WGS MLST was determined using CGE pipeline (https://cge.cbs.dtu.dk//services/MLST/) following Wirth et al. scheme² for all isolates except PN21. ^{**} Jaureguy et al. scheme³ was used to identify MLST type of strain PN21. [#] indicates that strains ff112, ff141 and ff156 are a group of wholly sensitive/susceptible *E. coli*, provided by Specialist Antimicrobial Chemotherapy Unit (SACU), Public Health Wales.

Supplementary Table2 Laboratory strains and plasmids used in this study										
Plasmid name	Host strain	Plasmid (size)	Colistin MIC (mg/L)	Reference						
mcr-1/pBAD	E.coli TOP10	~6000bp	2	This study						
pBAD alone	E.coli TOP10	~4100bp	0.25	Thermo Fisher, UK						
E.coli TOP10	-	-	0.25	Thermo Fisher, UK						
<i>mcr-1</i> /pSU18	E.coli TOP10	~4000bp	4	4						
GFP-pHT315	DH5 alpha	-	0.5	5						
bla _{TEM-1b} /pBAD	E.coli TOP10	~5000bp	0.25	This study						
E246A/pBAD	E.coli TOP10	~6000bp	0.25	This study						
<i>mcr-1</i> soluble domain /pBAD	E.coli TOP10	~5400bp	0.25	This study						

Supplementary Table3 Primers and probes used in this study										
Name	sequencing(5'-3')	size (bp)	Reference							
mcr-1 F	GCTACTGATCACCACGCTGT	953	This study							
mcr-1 R	TGGCAGCGACAAAGTCATCT									
<i>16S</i> qF	CATTGA CGTTACCCGCAGAA	100	6							
<i>16S</i> qF	CGCTTTACGCCCAGTAATTCC									
16S probe	FAM-CGTGCCAGCAGCCGCGGTA-TAMRA									
rpoB-qF3	TCCTTTCTATCCAGCTTGACTCGT	200	7							
rpoB-qR3	CGCAGTTTAACGCGCAGCGG									
rpoB-probe	HEX-ACGTCAGCTACCGCCTTGGCGAACCGGTGT- BHQ1									
mcr-1 qF	TGGCGTTCAGCAGTCATTAT		8							
mcr-1 qR	AGCTTACCCACCGAGTAGAT									
mcr-1 probe	ROX-AGTTTCTTTCGCGTGCATAAGCCG-BHQ1		Modified with Dye and quencher							
<i>mcr-1</i> soluble F	GGGGTACCACCATTTATCACGCCAAAGACG	969	This study							
<i>mcr-1</i> soluble R	CGGAATTCGCGGATGAATGCGGTGCG									
$bla_{\text{TEM-1b}}\mathbf{F}$	GGGGTACC ATGAGTATTCAACATTTTCGTGTCG	861	This study							
$bla_{\text{TEM-1b}}\mathbf{R}$	CGGAATTC TTACCAATGCTTAATCAGTGAGGC									

Supplementary Table4 MICs of colistin for mcr-1/pBAD after 14-day serial passage										
Passage		MIC	Cs of Colistin (mg/L)							
days	mcr-1(1)	mcr-1(2)	pBAD-1	pBAD-2	TOP10					
1	0.5	0.5	0.125	0.125	0.125					
2	2	1	0.125	0.125	0.25					
3	4	2	0.125	0.125	0.25					
4	4	4	0.125	0.125	0.25					
5	4	4	0.125	0.125	0.25					
6	8	4	0.125	0.125	0.25					
7	8	4	0.125	0.125	0.25					
8	8	16	0.125	0.125	0.25					
9	16	16	0.125	0.125	0.25					
10	16	16	0.125	0.125	0.25					
11	32	16	0.06	0.06	0.125					
12	32	16	0.06	0.06	0.125					
13	32	16	0.06	0.06	0.25					
14	32	32	0.06	0.125	0.25					

Supplementary Table 5 MICs of Colistin for seven wild type mcr-1-positive strains after 14-day serial passage										
Passage			MICs	of Colistin (mg	g/L)					
days	PN16	PN21	PN23	PN24	PN25	PN41	PN43			
0	8	4	8	4	8	4	4			
1	8	8	8	4	8	8	4			
3	8	8	8	4	8	8	4			
4	8	8	16	4	8	8	8			
5	16	8	16	4	8	8	8			
6	32	8	32	8	16	16	16			
7	16	16	32	8	16	16	16			
8	16	16	32	8	32	32	16			
9	16	32	128	16	32	32	32			
10	16	32	128	16	32	32	64			
11	16	64	128	16	64	32	128			
12	16	64	128	16	64	32	128			
13	32	64	128	16	64	32	256			
14	128	128	256	16	128	32	256			

Supplementary Table 6 Relative Fitness (RF) Mann-With Mannn-With Mann-With Mann Mann-With Mann-With											
RF(compared to the <i>mcr-1</i> /pBAD D0 Strain)	repeats	mean	SD	propagated errors	<i>p</i> -value						
E.coli TOP10	6	1.0960	0.0129	0.0171	0.132						
E.coli TOP10 pBAD	6	1.0955	0.0054	0.0134	0.0649						
E.coli TOP10 mcr-1/pBAD D3	6	1.0080	0.0062	0.0140	0.041*						
E.coli TOP10 mcr-1/pBAD D4	6	1.0132	0.0257	0.0283	0.3095						
<i>E.coli</i> TOP10 <i>mcr-1</i> /pBAD D8	6	0.8258	0.0088	0.0165	0.0022**						
E.coli TOP10 mcr-1/pBAD D14	6	0.7922	0.0084	0.0164	0.0022**						
RF(compared to each corresponding parent)											
PN16-D14	6	0.9380	0.0809	0.0875	0.132						
PN21-D14	6	0.4114	0.0293	0.0816	0.0022**						
PN23-D14	6	0.4083	0.0385	0.1404	0.0022**						
PN24-D14	6	0.4382	0.0133	0.0445	0.0022**						
PN25-D14	6	0.6047	0.0557	0.1196	0.0022**						
PN42-D14	6	0.5169	0.0309	0.0650	0.0022**						
PN43-D14	6	0.7779	0.0534	0.1003	0.0022**						
RF(compared to <i>mcr-1</i> /pBAD uninduced strain -0% [#])											
E.coli TOP10	6	1.0000	0.0147	0.0177	0.8182						
<i>E.coli</i> TOP10 <i>mcr-1</i> /pBAD +0.0002%	6	0.9992	0.0088	0.0132	0.6991						
<i>E.coli</i> TOP10 <i>mcr-1</i> /pBAD +0.002%	6	0.9991	0.0153	0.0182	1						
E.coli TOP10 mcr-1/pBAD +0.02%	6	0.7278	0.0031	0.0108	0.0022**						
E.coli TOP10 mcr-1/pBAD +0.2%	6	0.4272	0.0074	0.0262	0.0022**						

[#] indicates the concentration of L-arabinose (w/v). * indicates 0.01 < p value <0.05 and ** indicates p value <0.01

Supplementary Table 7 Antibiotic sensitivity profiles (mg/l) of MCRPEC and their respective HLCRMs														
Strains		CLT	CIP	ETP	CTX	AMK	TBM	GEN	NTF	CHL	TIG	FOS	VAN	AMP
PN16	Day 0	8	1	0.06	16	2	1	16	16	32	1	4	512	512
	Day13*	128	0.25	0.25	16	2	1	1	8	16	0.5	8	512	512
PN21	Day 0	4	4	0.06	64	2	8	128	16	32	8	256	512	512
	Day14	64	0.5	0.015	64	8	8	128	8	2	0.25	256	256	512
PN23	Day 0	8	0.25	0.06	4	2	1	8	16	32	1	256	512	512
	Day14	256	0.03	0.008	0.006	8	2	4	16	2	0.5	4	512	32
PN24	Day 0	4	1	0.015	64	2	8	256	16	128	8	1	512	512
	Day14	16	1	0.03	64	16	32	256	16	128	1	0.5	512	512
PN25	Day 0	8	0.008	0.015	4	2	1	1	8	4	1	1	256	512
	Day14	128	0.015	0.008	4	2	0.5	1	8	2	0.5	1	256	512
PN42	Day 0	4	32	0.015	8	2	2	32	32	128	2	1	512	512
	Day14	32	128	0.03	32	4	8	256	4	8	0.125	4	256	512
PN43	Day 0	4	128	0.06	32	2	4	64	8	256	4	1	512	512
	Day14	256	128	0.03	64	4	4	128	8	128	0.125	2	256	512

CLT, Colistin; CIP, Ciprofloxicin; ETP, Ertapenem; CTX, Cefotaxime; AMK, Amikacin; TBM, Tobramycin; GEN, Gentamicin; NTF, Nitrofurantoin; CHL, Chloramphenicol; TIG, Tigecycline; FOS, Fosfomycin; VAN, Vancomycin; AMP, Ampicillin. * for strain PN16, day-14 mutant are unable to grow, so we tested day-13 mutant instead.

Supplementary References

- 1. Wang Y, *et al.* Prevalence, risk factors, outcomes, and molecular epidemiology of mcr-1-positive Enterobacteriaceae in patients and healthy adults from China: an epidemiological and clinical study. *The Lancet Infectious Diseases* **17**, 390-399 (2017).
- 2. Wirth T, *et al.* Sex and virulence in Escherichia coli: an evolutionary perspective. *Molecular microbiology* **60**, 1136-1151 (2006).
- 3. Jaureguy F, *et al.* Phylogenetic and genomic diversity of human bacteremic Escherichia coli strains. *BMC genomics* **9**, 560 (2008).
- 4. Hinchliffe P, *et al.* Insights into the Mechanistic Basis of Plasmid-Mediated Colistin Resistance from Crystal Structures of the Catalytic Domain of MCR-1. *Sci Rep* **7**, 39392 (2017).
- 5. Daou N, *et al.* IIsA, a unique surface protein of Bacillus cereus required for iron acquisition from heme, hemoglobin and ferritin. *PLoS pathogens* **5**, e1000675 (2009).
- 6. Spano G, Beneduce L, Terzi V, Stanca AM, Massa S. Real-time PCR for the detection of Escherichia coli O157:H7 in dairy and cattle wastewater. *Letters in applied microbiology* **40**, 164-171 (2005).
- 7. Jones LS, *et al.* Characterization of plasmids in extensively drug-resistant acinetobacter strains isolated in India and Pakistan. *Antimicrob Agents Chemother* **59**, 923-929 (2015).
- 8. Irrgang A, *et al.* Prevalence of mcr-1 in E. coli from Livestock and Food in Germany, 2010-2015. *PloS one* **11**, e0159863 (2016).